Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Cipher's revised CIP-Tramadol ER NDA accepted for review by the FDA

June 19, 2008

New agents for treating neurological disorders disclosed in recent NeuroSearch and reMYND patents

June 19, 2008

Takeda requests reexamination of negative opinion for ramelteon given by EMEA's CHMP

June 18, 2008

Elan and Wyeth present top-line results from phase II bapineuzumab trial in AD

June 18, 2008

Acadia's ACP-104 for schizophrenia does not meet endpoints in phase IIb trial

June 17, 2008

Transdel and Cato collaborate on phase III Ketotrandel program

June 17, 2008

The FDA approves Lilly's Cymbalta for fibromyalgia

June 17, 2008

Victory Pharma's MGX-006 enters first of two clinical studies for pivotal development program

June 17, 2008

Dimethyl fumarate shows dual neuroprotective and antiinflammatory effects in multiple sclerosis

June 17, 2008

FDA approves Requip XL for Parkinson's disease

June 16, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...